TGF-β promotes production of ECM components and it was furthermore shown that the co-administration of TGF-β-blocking and anti-PD-L1 antibodies to an immune-excluded mouse model facilitated T-cell penetration into tumors and tumor regression [8]. This evidence concerns the gene TGFB1 and neoplasm.